Inovio Pharmaceuticals Inc (INO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inovio Pharmaceuticals Inc (INO) has a cash flow conversion efficiency ratio of 2.795x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.57 Million) by net assets ($-7.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See INO defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Inovio Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Inovio Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inovio Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inovio Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Genasys Inc
NASDAQ:GNSS
|
-3.076x |
|
Sena Development Public Company Limited
BK:SENA
|
0.033x |
|
GeeCee Ventures Limited
NSE:GEECEE
|
0.109x |
|
Taekyung BK Co Ltd
KO:014580
|
0.037x |
|
Nurminen Logistics Oyj
HE:NLG1V
|
0.125x |
|
51 CREDIT CARD DL-00001
F:2JY
|
N/A |
|
Rorze Systems Corporation
KQ:071280
|
-0.028x |
|
Ribbon Acquisition Corp Unit
NASDAQ:RIBBU
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Inovio Pharmaceuticals Inc (1998–2024)
The table below shows the annual cash flow conversion efficiency of Inovio Pharmaceuticals Inc from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see Inovio Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $68.50 Million | $-104.08 Million | -1.519x | -43.36% |
| 2023-12-31 | $117.35 Million | $-124.37 Million | -1.060x | -8.99% |
| 2022-12-31 | $222.36 Million | $-216.22 Million | -0.972x | -80.16% |
| 2021-12-31 | $399.67 Million | $-215.71 Million | -0.540x | -39.84% |
| 2020-12-31 | $461.14 Million | $-177.98 Million | -0.386x | +97.87% |
| 2019-12-31 | $5.40 Million | $-97.85 Million | -18.104x | -2042.27% |
| 2018-12-31 | $87.03 Million | $-73.55 Million | -0.845x | -90.50% |
| 2017-12-31 | $142.49 Million | $-63.21 Million | -0.444x | +12.51% |
| 2016-12-31 | $123.38 Million | $-62.56 Million | -0.507x | -617.11% |
| 2015-12-31 | $175.93 Million | $-12.44 Million | -0.071x | +73.56% |
| 2014-12-31 | $111.54 Million | $-29.82 Million | -0.267x | +8.04% |
| 2013-12-31 | $52.90 Million | $-15.38 Million | -0.291x | +54.57% |
| 2012-12-31 | $34.86 Million | $-22.31 Million | -0.640x | -55.04% |
| 2011-12-31 | $47.86 Million | $-19.76 Million | -0.413x | -62.86% |
| 2010-12-31 | $47.10 Million | $-11.94 Million | -0.253x | -10.13% |
| 2009-12-31 | $61.18 Million | $-14.08 Million | -0.230x | +60.48% |
| 2008-12-31 | $19.11 Million | $-11.13 Million | -0.582x | -56.97% |
| 2007-12-31 | $31.03 Million | $-11.51 Million | -0.371x | -23.80% |
| 2006-12-31 | $23.50 Million | $-7.04 Million | -0.300x | +42.99% |
| 2005-12-31 | $23.47 Million | $-12.34 Million | -0.526x | -20.20% |
| 2004-12-31 | $15.55 Million | $-6.80 Million | -0.437x | -139.45% |
| 2003-12-31 | $15.05 Million | $-2.75 Million | -0.183x | +86.28% |
| 2002-12-31 | $3.73 Million | $-4.96 Million | -1.331x | +21.06% |
| 2001-12-31 | $4.96 Million | $-8.37 Million | -1.687x | -89.75% |
| 2000-12-31 | $9.89 Million | $-8.79 Million | -0.889x | -66.92% |
| 1999-12-31 | $11.83 Million | $-6.30 Million | -0.532x | +29.85% |
| 1998-12-31 | $8.30 Million | $-6.30 Million | -0.759x | -- |
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA s… Read more